Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > patent fluffing NR. his interview was overstated.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Post by bioinvestors416on Nov 30, 2022 3:52pm
132 Views
Post# 35140891

patent fluffing NR. his interview was overstated.

patent fluffing NR. his interview was overstated. the patents in the latest NR are not yet issued only filed. in his interview ceo spoke as though the patents were issued and his 'me too product' is ip protected at this time.  that is incorrect and overstated.  will take at least 1.5 years before it may be issued.  so any license partner has to weigh the risk of putting in money on this drug and getting a patent rejected.  unlikely but it happens.   normally i have seen patent approvals as being news worthy.  this is desperate and trying to pump a nothing burger.  or for my dumb GTA  friends; a overrated burger from Webers.  
 
every biotech ceo talks like he has a blckbuster without money or data to support wild affirmations.  

show us the data; because facts matter.  


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities